Drug development is a time consuming, complex, risky and expensive venture. There is an increasing requirement to find ways to accelerate and reduce the cost of decision making so that only the best candidate molecules progress to the later stages of drug development.

Imanova is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding.

Established in 2011 Imanova was formed in an innovative alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London to act as a centre of excellence for imaging sciences in the Uk and as a conduit between academia and industry. Since August 2017 Imanova is part of Invicro.

Since inception, Imanova has completed over 93 clinical studies and has successfully developed and-or implemented over 30 radioligands for pre-clinical and clinical use, and is in a unique position to facilitate productive, mutually beneficial relationships between academia and industry.

26 September 2017
Konica Minolta Accelerates Expansion of Precision Medicine Business through Acquisition of US-based Pharmaceutical Research Company, Invicro Through molecular digital imaging technology, acquisition o...